Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Sex differences in the incidence, mortality, and survival outcomes of lymphoma subtypes

View through CrossRef
Abstract Background The phenomenon of males exhibiting higher lymphoma incidence and mortality rates than females has been widely recognized, and many survival analyses of certain lymphoma subtypes have incorporated sex as a critical prognostic determinant. However, comprehensive research on these sex-based differences in lymphomas remains limited. Methods This study aimed to conduct an integrated population-based analysis of sex-based disparities across various lymphoma subtypes using the Surveillance, Epidemiology, and End Results (SEER) database. We assessed the age-adjusted incidence rates of cases in the SEER22 and incidence-based mortality rates in the SEER12. The rates were stratified according to subtype, sex, race/ethnicity (incidence and mortality), age at diagnosis, and year of diagnosis (incidence only). Furthermore, we compared the risks of all-cause mortality, cancer-specific mortality, and cardiovascular disease-related mortality based on sex in SEER17. Results Our findings revealed that males had a higher likelihood of developing lymphoma and exhibited higher mortality rates than females for most lymphoma subtypes. These sex-based disparities in incidence and mortality were relatively consistent across five racial/ethnic groups. However, sex-based disparities in cancer incidence varied among age groups, and a trend toward narrowing differences with increasing age was observed in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), mantle cell lymphoma, and Burkitt lymphoma. Over the past two decades, trends in sex-based disparities of lymphoma incidence have remained stable. Regarding survival outcomes, males faced an increased risk of death compared to females for most lymphoma subtypes, except for NLPHL. Conclusions The results of our study underscore the complex and multifaceted nature of sex-based disparities in lymphoma and may offer valuable guidance for future research to unravel the potential causes of these differences.
Title: Sex differences in the incidence, mortality, and survival outcomes of lymphoma subtypes
Description:
Abstract Background The phenomenon of males exhibiting higher lymphoma incidence and mortality rates than females has been widely recognized, and many survival analyses of certain lymphoma subtypes have incorporated sex as a critical prognostic determinant.
However, comprehensive research on these sex-based differences in lymphomas remains limited.
Methods This study aimed to conduct an integrated population-based analysis of sex-based disparities across various lymphoma subtypes using the Surveillance, Epidemiology, and End Results (SEER) database.
We assessed the age-adjusted incidence rates of cases in the SEER22 and incidence-based mortality rates in the SEER12.
The rates were stratified according to subtype, sex, race/ethnicity (incidence and mortality), age at diagnosis, and year of diagnosis (incidence only).
Furthermore, we compared the risks of all-cause mortality, cancer-specific mortality, and cardiovascular disease-related mortality based on sex in SEER17.
Results Our findings revealed that males had a higher likelihood of developing lymphoma and exhibited higher mortality rates than females for most lymphoma subtypes.
These sex-based disparities in incidence and mortality were relatively consistent across five racial/ethnic groups.
However, sex-based disparities in cancer incidence varied among age groups, and a trend toward narrowing differences with increasing age was observed in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), mantle cell lymphoma, and Burkitt lymphoma.
Over the past two decades, trends in sex-based disparities of lymphoma incidence have remained stable.
Regarding survival outcomes, males faced an increased risk of death compared to females for most lymphoma subtypes, except for NLPHL.
Conclusions The results of our study underscore the complex and multifaceted nature of sex-based disparities in lymphoma and may offer valuable guidance for future research to unravel the potential causes of these differences.

Related Results

Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract Introduction Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Exploring the Association between Lymphoma and Inflammatory Bowel Disease in an Inner-City Academic Institution
Exploring the Association between Lymphoma and Inflammatory Bowel Disease in an Inner-City Academic Institution
Introduction: The incidence of lymphoma has been increasing over the past several decades, with data showing an estimated annual percentage change of 0.56%. There...
Lymphomas
Lymphomas
Lymphoma is the fifth most common type of cancer in the United States, with 74,490 new cases estimated in 2009. Approximately 15% of patients with lymphoma have Hodgkin lymphoma; t...
Lymphomas
Lymphomas
Lymphoma is the fifth most common type of cancer in the United States, with 74,490 new cases estimated in 2009. Approximately 15% of patients with lymphoma have Hodgkin lymphoma; t...
The Analysis of HIV-Associated Lymphoma in Japan
The Analysis of HIV-Associated Lymphoma in Japan
Abstract Background. The recent advance of antiretroviral therapy decreased the morbidity of opportunistic infections. However, the incidence of HIV-a...
Beneficios de la quimioterapia adyuvante en los resultados de supervivencia del cáncer de mama triple negativo pT1N0M0
Beneficios de la quimioterapia adyuvante en los resultados de supervivencia del cáncer de mama triple negativo pT1N0M0
Introduction Collaborative health research has proven to be an effective approach to addressing regional and international challenges in the diagnosis, treatment, and management o...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top